Evidence map›Paper›PMID 41922226›Full record

ArticleJournal of clinical and experimental hematopathology : JCEH2026

CD83 as a novel prognostic biomarker for diffuse large B-cell lymphoma arising in immune deficiency/dysregulation among rheumatoid arthritis patients treated with methotrexate.

Keisuke Sawada, Takumi Takahashi, Yuki Fukumura, Hiroko Onagi, Karin Ashizawa, Takahisa Yamashita, Wataru Yamamoto, Natsuko Takayanagi, Akiko Adachi, Makoto Kashimura and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical and experimental hematopathology : JCEH, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Keisuke SawadaDepartment of Pathology, Saitama Medical Center, Saitama Medical University, Saitama, Japan.
Takumi TakahashiDepartment of Oral Maxillofacial Surgery, Saitama Medical Center, Saitama Medical University, Saitama, Japan.
Yuki FukumuraDepartment of Human Pathology, Juntendo University School of Medicine, Tokyo, Japan.
Hiroko OnagiDepartment of Human Pathology, Juntendo University School of Medicine, Tokyo, Japan.
Karin AshizawaDepartment of Human Pathology, Juntendo University School of Medicine, Tokyo, Japan.
Takahisa YamashitaDepartment of Pathology, Saitama Medical Center, Saitama Medical University, Saitama, Japan.
Wataru YamamotoDepartment of Pathology, Saitama Medical Center, Saitama Medical University, Saitama, Japan.
Natsuko TakayanagiDepartment of Pathology, Saitama Medical Center, Saitama Medical University, Saitama, Japan.
Akiko AdachiDepartment of Diagnostic Pathology, Saitama Red Cross Hospital, Saitama, Japan.
Makoto KashimuraDepartment of Hematology, Shinmatsudo Central General Hospital, Chiba, Japan.
Takayuki TabayashiDepartment of Hematology, Saitama Medical Center Saitama Medical University, Saitama, Japan.
Jun-Ichi TamaruDepartment of Pathology, Saitama Medical Center, Saitama Medical University, Saitama, Japan.
Morihiro HigashiDepartment of Pathology, Saitama Medical Center, Saitama Medical University, Saitama, Japan.
Shuji MomoseDepartment of Pathology, Saitama Medical Center, Saitama Medical University, Saitama, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of methotrexate-associated lymphoma arising in immune deficiency/dysregulation (MTX-associated IDD-DLBCL) among rheumatoid arthritis patients treated with MTX and is characterized by frequent spontaneous regression (SR) after MTX withdrawal. However, some patients do not achieve SR and have poor outcomes. Epstein-Barr virus (EBV) infection correlates with frequent SR but does not fully explain clinical heterogeneity. We investigated prognostic factors irrespective of EBV infection status. We analyzed 21 MTX-associated IDD-DLBCL cases applying the nCounter PanCancer Immune Profiling Panel and immunohistochemistry (IHC) to identify predictors of non-SR cases. Ten patients were classified as SR and 11 as non-SR. Gene expression profiling revealed higher expression of CD83, ICOSLG, IL21R, BCL6, CD40, PAX5, CXCR5, CD79A, DMBT1, and TNFRSF13C in non-SR cases. We therefore focused on CD83, which showed the highest fold change and the most significant P value among these markers. Although CD83 is reported to be a surface marker of mature dendritic cells, IHC analysis revealed that CD83 was more frequently expressed on tumor cells than on dendritic cells. High CD83 IHC positivity (≥15%) in tumor cells correlated with mRNA levels and predicted non-SR after MTX withdrawal. Multivariate analysis identified CD83 IHC high expression as an independent predictor of non-SR cases. High CD83 expression is an independent prognostic factor in MTX-associated IDD-DLBCL, and combined evaluation may refine risk stratification and guide clinical decisions.

Indexed as

Antigens, CDArthritis, RheumatoidBiomarkers, TumorImmunoglobulinsLymphoma, Large B-Cell, DiffuseMembrane GlycoproteinsMethotrexateAgedCD83 AntigenFemaleHumansMaleMiddle AgedPrognosisAntigens, CDBiomarkers, TumorCD83 AntigenImmunoglobulinsMembrane GlycoproteinsMethotrexateCD83diffuse large B-cell lymphomaimmune deficiency/dysregulationmethotrexaterheumatoid arthritis

Identifiers

PMID41922226
PMCPMC13160655

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.